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A synthetic peptide corresponding to the 106–126 amy-
loidogenic region of the cellular human prion protein
(PrPc) is useful for in vitro study of prion-induced neuro-
nal cell death. The aim of the present work was to
examine the implication of the cellular prion protein in
the toxicity mechanism induced by PrP 106–126. The
effect of PrP 106–126 was investigated both on human
neuroblastoma SH-SY5Y cells and on SH-SY5Y over-
expressing murine cellular prions (wtPrP). We show by
metabolic assay tests and ATP assays that PrPc ex-
pression does not modulate the toxicity of the prion
peptide. Moreover, we investigated the effect of this
peptide on an established non neuronal model, rabbit
kidney epithelial A74 cells that express a doxycycline-
inducible murine PrPc gene. We show for the first time
that the prion peptide 106–126 does not exert any toxic
effect on this cell line in the presence or absence of
doxycycline. Our results show that the PrP 106–126-
induced cell alteration is independent of PrPc ex-
pression. Rather, it seems to act via an interaction
with lipidic components of the plasma membrane as
strengthened by our results showing the differential
susceptibility of neuronal and non neuronal cell lines
that significantly differ by their membrane fatty acid
composition. VC 2006 Wiley-Liss, Inc.
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Prion diseases are fatal neurodegenerative disorders
affecting the central nervous system (CNS) of humans
and animals and characterized by a neuronal vacuolation,
astrocytosis, and progressive neuronal degeneration (Gaj-
dusek et al., 1966; Clinton et al., 1993; Fraser, 1993;
Jeffrey et al., 2000). These diseases are caused by the in-
tracerebral accumulation of an abnormal isoform of the
cellular prion protein (PrPc), named PrPsc (PrP scrapie)
(Caughey and Lansbury, 2003; Collins et al., 2004;
Prusiner, 1998). Many lines of evidence suggest that
PrPc acts as a template that promotes the conversion of
PrPc to PrPsc (Caughey and Raymond, 1991). The plasma
membrane seems to play a key role in the molecular
mechanism implicated in this conversion. Supporting this
hypothesis is the subcellular site for the formation of
PrPsc; indeed, the conversion occurs after PrPc reaches the
plasma membrane (Taraboulos et al., 1995). Moreover,
Baron et al. (2002) have shown, using purified raft mem-
branes, that the conversion of raft-associated GPI-anch-
ored PrPc to PrPsc requires the insertion of PrPsc into the
lipid membrane. However, the mode of interaction of
prion proteins with the membranes has not as yet been
elucidated: does the interaction occur via a direct insertion
of the prion protein into the lipid bilayer or via a putative
membrane receptor?
We have shown previously that PrP (106–126), a
peptide largely used as a model to study the PrPsc in-
duced neurotoxicity, destabilizes lipid vesicles mimicking
the composition of neuronal membranes (liposomes) and
induces liposome fusion (Dupiereux et al., 2005a). This
destabilization mechanism occurs at low concentrations
of the peptide (from 2–10 lM) and via a membrane in-
teraction, as supported by the integrity membrane assay
measuring the release of the intracellular lactate dehydro-
genase (LDH assay). These results are in agreement with
other previous reports. Indeed, several studies have
shown that PrP 106–126 forms ion channels in planar
lipid bilayers (Arispe et al., 1996; Kawahara et al., 2000)
and that it increases the membrane microviscosity of
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neurons and astrocytes (Diomede et al., 1996; Salmona
et al., 1997). Nevertheless, the role of the cellular prion
protein in the membrane destabilization mechanism in-
duced by this peptide remains as yet non-elucidated.
Several works, using knock-out cell lines, show that
PrPc expression is necessary for the cellular toxicity in-
duced by this peptide (Brown et al., 1994; Chabry et al.,
2003a; Fioriti et al., 2005b). These results indicate that
the membrane destabilization induced by PrP 106–126
could arise from a dual mechanism: a direct peptide in-
sertion in the lipid bilayer or an interaction with PrPc.
To investigate the role of PrPc in the neurotoxicity
induced by the 106–126 prion peptide we have examined
whether an overexpression of murine PrPc (wtPrP) (Walms-
ley et al., 2001a) changes the susceptibility of neurons to the
peptide. Our results indicate that the toxicity induced by the
106–126 peptide is independent of PrPc expression level.
Moreover, the addition of an anti-prion antibody (SAF 34),
able to decrease the basal level of PrPc, induces, in our ex-
perimental conditions, non-significant changes in toxicity,
showing that the PrPc expression is not necessary for the
PrP 106–126 toxicity. Additionally, to study the potential
relationship between PrP 106–126 and lipidic components
of the plasma membrane, we have investigated the effect of
the peptide on non-neuronal cells, rabbit kidney epithelial
(A74) cells, which express a doxycycline-inducible murine
PrPc gene. We have shown that this cell line is resistant to
the PrP 106–126 toxicity confirming that the toxicity of this
peptide is independent of PrPc expression levels. We there-
fore suggest that this toxicity might be in relation with the
lipidic composition of the cell membranes as strengthened
by our results after the comparison of the fatty acid compo-




PrP106–126, derived from amino residues 106–126 of
the human prion protein sequence (sequence: Lys-Thr-Asn-
Met-Lys-His-Met-Ala-Gly-Ala-Ala-Ala-Ala-Gly-Ala-Val-Val-
Gly-Gly-Leu-Gly) was purchased from Eurogentec SAAQ3 and
scrambled peptide containing the same amino acids in a ran-
dom order (sequence: Asn-Gly-Ala-Lys-Ala-Leu-Met-Gly-
Gly-His-Gly-Ala-Thr-Lys-Val-Met-Val-Gly-Ala-Ala-Ala) was
purchased from BachemAQ3 . Palmitic acid was purchased from
Sigma AldrichAQ3 . The secondary antibody rabbit antimouse IgG,
A, M/FITC was purchased from SerotecAQ3 and Streptavidine/
FITC from PharmingenAQ3 . Rabbit polyclonal antibody P45-66
was supplied by Dr. D. Harris (Washington University, St.
Louis, MO) and the secondary antibody HRP-coupled rabbit
IgG was from Sigma (St. Louis, MO). The mouse anti-PrPC
SAF34 was kindly provided by Dr. J. Grassi from CEA of
Paris. All cell culture supplies were purchased from Life Tech-
nologies Inc.AQ3 and fatty acid supplies were from VWR Interna-
tionalAQ3 and Sigma-Aldrich.
Cell Culture
The human neuroblastoma cell line SH-SY5Y, kindly
provided by Professor N.M. Hooper, and the same line stably
transfected with the wild-type murine PrP (wtPrP) (Walmsley
et al., 2001b) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Life Technologies Inc. AQ3) supplemented
with 10% fetal bovine serum (FBS) (Life Technologies Inc.),
1% penicillin/streptomycin (Life Technologies Inc.). Cells
were maintained at 378C in a humidified incubator with 95%
air and 5% CO2. For experiments, cells were maintained in
FBS-free DMEM medium containing the neuroblastoma growth
supplement N2 (Life Technologies Inc.) and 1% penicillin/strep-
tomycin.
The A74 cell line, initially generated in the laboratory
of Drs. Vilette and Laude (INRA, Jouy-en-Josas, France), was
established by transfecting rabbit kidney epithelial cells with
murine PrPc. The expression of the murine PrP is doxycy-
cline-inducible via a tetracycline-inducible (tet-on) system
(Vilette et al., 2001d). The stable transfectants were selected in
the presence of puromycin (10 lg/ml). A74 were cultured in
modified Eagle’s medium (MEM) supplemented with 10%
heat-inactivated FBS and 1% penicillin/streptomycin. Cells
were grown at 378C in a humidified incubator with 95% air
and 5% CO2. For experiments, cells were maintained in
MEM medium containing 2% FBS and 1% penicillin/strep-
tomycin.
Cell Metabolism Assays
SH-SY5Y cells were seeded into 96-well culture plates.
Sixteen hours after seeding, the medium was replaced with se-
rum-free DMEM containing the neuroblastoma growth sup-
plement N2 and the cells were treated for 24 hr with different
concentrations of PrP 106–126 (10–200 lM). The treatment
with the anti-prion antibody SAF 34 was carried out by incu-
bating the cells with an optimized concentration of antibody
SAF 34 (1 lg/ml) and after 3 hr, the medium was replaced
with fresh medium and cotreated for an additional 24 hr with
PrP 106–126 (200 lM) and SAF 34 (1 lg/ml).
A74 cell line in 96-well culture plates were grown over-
night in MEM supplemented with 2% FBS. The next day the
medium was changed and the cells were treated with doxycy-
cline at 500 ng/ml to induce PrPc expression. After 24 hr the
cells were incubated with PrP 106–126 (50–100 lM) for an
additional 24 hr.
To study the effect of lipidic factors, such as palmitic
acid, on the toxicity effect of the 106–126 peptide, both the
neuronal (SH-SY5Y) and non neuronal cells (A74) were incu-
bated with palmitic acid at a final concentration of 25 lM for
16 hr. Cells were then treated with the palmitic acid (25 lM)
and PrP 106–126 (200 lM) for additional 24 hr.
The cell proliferation was measured using the CellTiter
96 AQueous Non-Radioactive Cell Proliferation Assay (Prom-
ega AQ3) according to the manufacturer’s instruction. The cell tox-
icity was assessed quantitatively by MTS assay in the presence
of phenazine methosulfate (PMS). After addition of 20 ll of
the combined MTS/PMS solution in each well, the plates
were incubated at 378C in a humidified atmosphere contain-
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ing 5% CO2 for 2 hr. The absorbance was measured at
490 nm (EL 312e microplate Bio-Tek InstrumentsAQ3 ).
All MTS assays were carried out in triplicate. MTS assay
is a sensitive indicator of mitochondrial activity.
Cell Toxicity Test
Measurement of ATP levels allows to estimate cellular
suffering. Human SH-SY5Y cells were seeded into 96-well
culture plates. Sixteen hours after seeding, the medium was
replaced with serum-free medium containing the neuroblastoma
growth supplement N2 and the cells were treated for 24 hr with
different concentrations of PrP 106–126 (10–200 lM).
ATP was quantified using the CellTiter-Glo Lumines-
cent Cell Viability Assay (Promega) according to the manufac-
turer’s instruction. The reagent is a buffered solution contain-
ing detergents to break the cell membrane, releasing ATP im-
mediately on addition to wells and ATPase inhibitors to
stabilize ATP once it is released from cells. After 106–126
peptide treatment, assay plates were removed from the incuba-
tor and 100 ll of CellTiter-Glo Assay reagent, equilibrated to
room temperature, was added to each well. Plates were shaken
for 2 min to mix the contents of the wells. After a 10–15 min
incubation at room temperature, luminescence was deter-
mined using a Microplate Luminometer MPL2 (Berthold).
PrPc Labeling for Confocal Microscopy
A total of 20,000 SH-SY5Y or wtPrP cells were seeded
and left to adhere for 5 hr in 50 ll DMEM 10% FBS and 1%
penicillin/streptomycin on uncoated 12-mm circular glass
coverslips placed in 24-well culture plates (Greiner). Fresh
medium (450 ll) was added. Cells were cultured for 24 hr
then fixed during 20 min in 1:1 acetone/methanol at 208C.
The acetone/methanol was discarded and the coverslips were
kept at 208C until use. The cells were then dehydrated at
room temperature and rehydrated in phosphate buffered saline
(PBS) before labeling. PrPC was revealedAQ6 at room temperature
as follows: cells were incubated 1 hr with SAF34 10 lg/ml in
PBS, washed 3 times with PBS, incubated 30 min with the
rabbit anti-mouse IgG, A, M/FITC 1/1,000 in PBS, followed
by washing 3 times in PBS. The coverslips were mounted on
microscopy glass slides using DAKO fluorescence mounting
medium before observation with a Leica TCS SL SP2 confo-
cal microscope (Leica, Belgium) equipped with Argon, Ne/
Kr, and He/Ne lasers. One-step scans were carried out. A se-
ries of 20 images were acquired and stacked using the Maxi-
mum Projection.
Western Blotting
A74 cells (seeding density 5 3 106) were grown in
T75 cm2 flasks. The next day the cells were treated for an
additional 24 hr with different concentrations of doxycycline
(10–500 ng/ml). After 24 hr, the cells were washed twice
with cold PBS, calcium- and magnesium-free, and lysed for
30 min at 48C in Triton-deoxycholate lysis buffer (13 buffer
is 150 mM NaCl, 0.5% Triton X-100, 0.5% sodium deoxy-
cholate, and 50 mM Tris-HCl, pH 7.5) containing protease
inhibitors. After 1 min of centrifugation at 10,000g, the super-
natant was collected, and its protein concentration was meas-
ured by the BCA assay (Pierce). The equivalent of 20 lg of
total protein in SDS loading buffer was subjected to 12%
SDS-PAGE electrophoresis followed by electroblotting on
polyvinylidene difluoride in Tris-glycine buffer containing
20% methanol. The membrane was blocked with 5% non-fat
dry milk in TBST (0.1% Tween 20, 100 mM NaCl, 10 mM
Tris-HCL, pH 7.8) for 1 hr at room temperature, and PrP
was detected by immunoblotting with P45-66 antibody. After
adding the second antibody (horseradish peroxidase-coupled
rabbit IgG), immunoreactive proteins were detected with the
ECL Western blot system.
Flow Cytometry
Human SH-SY5Y cells seeded in 6-well plates (1.6 3
106 cells/well) were incubated for 24 hr in the presence or
absence of SAF34 at 1 lg/ml. The cells were then rinsed in
PBS and collected after incubation at 378C for 10 min with
500 ll of cell dissociation buffer (enzyme free; Invitrogen).
Samples of 100 ll containing 1 3 106 SH-SY5Y cells were
incubated with the biotinylated antibody SAF34 (10 lg/ml)
for 30 min at 48C in PBS, washed and then incubated for an
additional 30 min with a fluorescein isothiocyanate-conjugated
streptavidin (diluted 1/1,000). The control cells were not in-
cubated with the antibody (biotinylated SAF34). After rinsing,
the resuspended cells were immediately analyzed in a FACS-
can (Becton-Dickinson, Sunnyvale, CA).
Fatty Acid Analysis
Phospholipid extraction was carried out on SH-SY5Y
and A74 cells. The cells were placed in 0.1 ml of a mixture of
butylated hydroxy toluene (BHT)/CH2Cl2 (0.0204 mg of
BHT in 1 ml of CH2Cl2) and 4 g of Na2SO4 and crushed
with a cooled mortar. After 1 min, Celite 545 (3 g) was added
and the cells were further crushed for 1 min. The mixture
was transferred in a chromatography column filed with glass
wool and 2 g of a mixture of CaHPO4. AQ42H20 and Celite 545
in a proportion of 1:9. The mortar was washed with 15 ml of
the mixture CH2Cl2/CH3OH (90:10) and transferred onto
the column. About 50 ml of the mixture CH2Cl2/CH3OH
was added and the eluent was collected and diluted in 1 ml of
ethyl acetate and the phospholipid fatty acids were separated
with a SPE method (solid phase extraction). The trans-esterifi-
cation procedure of the carboxylic group with methanol in hot
acid medium produced the fatty acid methyl esters (FAME).
The FAME were separated by gas chromatography (GC), Agi-
lent 6890, on a capillary column with helium as the carrier gas.
The analysis was realized with a flame ionization detector. The
chem station software, on the GC Agilent 6890, measured the
height of the different peaks and calculated the concentrations
of the different FAME.
RESULTS
Toxicity of PrP 106–126 Is Independent of the
Level of Cellular PrP Expression
To study the relationship between the toxicity of
PrP 106–126 and the expression levels of the cellular
prion protein, we compared the effect of the peptide on
SH-SY5Y neuroblastoma cells, expressing a basal level of
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human PrP, with the same SH-SY5Y cells overexpress-
ing a murine prion protein (wtPrP). The level of PrP
expression was analyzed by confocal microscopy using
the SAF 34 antibody. As shown in FigureF1 1, a more
intense immunostaining was observed on wtPrP cells,
whereas a weak staining was detected on SH-SY5Y cells.
These results confirm that the wtPrP cells overexpress
PrP in comparison with the SH-SY5Y cells that express
a basal level of PrP.
Neuronal injuries induced by the 106–126 peptide
were monitored by measuring the reduction of the mi-
tochondrial activity using the MTS assay and the ATP
assay monitoring cell alteration. MTS is converted to a
formazan product by dehydrogenase enzymes, which
become inactive as the cell suffers. Measurement of this
formazan product is an indicator of cell metabolism and
viability. As shown in FigureF2 2A, PrP 106–126 treat-
ment (10–200 lM) induces a concentration-dependent
toxicity for both SH-SY5Y and wtPrP cells. No signifi-
cant difference in the toxicity induced by the peptide
was observed between the two cell lines; indeed, PrP
106–126 caused a 50% decrease at 200 lM in SH-SY5Y
and wtPrP (45.9 6 3.6% and 55.8 6 11.2%, respec-
tively). In contrast, 200 lM of scrambled peptide had no
effect (99.5 6 0.96%) (Fig. 2B). These data indicate that
the toxicity induced by the peptide 106–126 is inde-
pendent of the level of PrP expression.
By using the ATP assay, the effect of PrP 106–126
on the intracellular content of ATP was measured in
relation with the level of PrP expression (Fig. F33). A
24 hr treatment with different concentrations of the pep-
tide (10–200 lM) induced a dose-dependent decrease in
the ATP level without any difference between the two
tested cell lines (SH-SY5Y and WtPrP). These data are
in agreement with those obtained with the MTS assay
confirming that the toxicity induced by PrP 106–126 is
independent of the level of PrPc expression.
To elucidate whether the neurotoxic effect of PrP
106–126 observed on the neuroblastoma cell lines is
mediated by the PrP basal level expression, we blocked
PrPc surface expression with an anti-PrP antibody. We
used SAF34, known to interact with PrPc and prevent
the interaction between PrPc and PrPsc (Perrier et al.,
2004; Feraudet et al., 2005a).
To investigate the effect of the SAF34 antibody on
PrPc expression, we analyzed by flow cytometry the level
of PrPc on SH-SY5Y neuroblastoma cells incubated for
24 hr in the presence or absence of the SAF34 antibody.
As shown in Figure F44a, in the absence of SAF34 treat-
ment, the neuroblastoma cells SH-SY5Y present a posi-
tive immunostaining indicating that they express a basal
level of PrPc as shown by confocal microscopy (Fig. 1).
Conversely, when the cells were pre-incubated with the
SAF34 antibody for 24 hr (Fig. 4b) no staining was
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Fig. 1. Immunofluorescence detection
of the prion protein on SH-SY5Y and
wtPrP cells. PrPc was detected using
SAF 34 antibody (10 lg/ml) followed
by a FITC-conjugated secondary anti-
body. Cells were viewed by a Leica
laser scanning confocal microscope. A
more pronounced staining was ob-
served on wtPrP cells indicating a high
expression of PrP. Figure can be viewed
in color online via www.interscience.
wiley.com.
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observed, suggesting that PrPc was either cleared or
masked by the interaction with SAF34.
To study the effect of the antibody treatment on
the toxicity induced by the prion peptide 106–126, we
have carried out toxicity assays on cells treated for 24 hr
with the antibody. The MTS assay (Fig.F5 5) showed that
the measured values remained equivalent in the presence
of the SAF antibody suggesting that the toxicity of the
peptide is independent of the cellular prion protein.
We have shown previously that the PrP 106–126
induced a destabilization of lipidic liposomal vesicles
indicating that the toxicity effect of this peptide could
occur via a membrane interaction (Dupiereux et al.,
2005b); this in turn suggests that lipidic components
could play a key role in the toxicity of PrP 106–126
peptide.
Rabbit Kidney Epithelial Cells Are Resistant
to Prion Peptide 106–126 Toxicity
To further investigate the relationship between the
basal expression of PrPc and the neurotoxicity induced
by the peptide 106–126 we used a cell model (rabbit
kidney epithelial cells) that expresses low levels of PrPc
but in which murine PrPc can be selectively induced by
doxycycline (Vilette et al., 2001c).
Treatment with doxycycline (10–1,000 ng/ml) in-
duced the expression of PrPc, as shown by Western blot-
ting (Fig. F66). Conversely, in the absence of doxycycline
no endogenous PrPc was detected in these cells (Vilette
et al., 2001b).
In these cells, we have shown that the absence or
the presence of doxycycline (absence or presence of
PrPC expression), does not change the PrP 106–126 tox-
icity (Fig. F77). The incompatibility between the human
sequence of PrP 106–126 and the murine PrP can be
discarded; indeed, we have shown by MTS assay, that
the same peptide is neurotoxic for murine neuroblastoma
cells (N2a) expressing a murine PrP in the same concen-
tration range of PrP 106–126 inducing 50% cell death at
200 lM (data not shown). These data indicate that the
PrP expression is not required for PrP106–126 toxicity.
The difference in the susceptibility of these two
tested cell lines (neuronal and non neuronal), toward the
PrP 106–126 peptide, might be related to the composi-
tion of the lipidic cell membrane. To study the putative
implication of the lipids, the fatty acid composition of
the cellular membrane of SH-SY5Y and A74 was com-
pared (Table T1I). Significant differences were observed
between these two cell lines and in particular in the
composition of their unsaturated fatty acids. Indeed, the
content in unsaturated fatty acids in the neuroblastoma
cells was significantly higher than in the rabbit kidney
epithelial cells. The most unsaturated fatty acids in the
neuronal cells were palmitoleic acid (16:1), vaccenic acid
(18:1), arachidonic acid (20:4), docosapentaenoic acid
(22:5), and docosahexaenoic acid (22:6). These data sug-
gest that the susceptibility to the prion peptide 106–126
could be related to the fatty acid composition of the cel-
lular membranes. Our observation reinforces the hypoth-
esis of a direct interaction of the prion 106–126 peptide
with the lipidic membrane.
Enhanced Toxicity of PrP 106–126 on the
Neuroblastoma Cell Line in the
Presence of Palmitic Acid
Based on fatty acid analysis we observed different
saturated and non saturated fatty acid composition
between the neuronal and non neuronal cell lines used
in this study. Indeed, amongst others, palmitic acid, vac-
cenic acid and docosahexaenoic acid were present in
low amounts in the PrP 106–126 resistant non neuronal
J_ID: Z3P Customer A_ID: 20965 Cadmus Art: JNR3336 Date: 26-MAY-06 Stage: I Page: 5
Fig. 2. PrP 106–126 neurotoxicity in SH-SY5Y and wtPrP cells.
PrP 106–126 (A) or scrambled (control) PrP 106–126 (B) was added
at concentrations of 10–200 lM. Cell metabolism (viability) was
measured 24 hr later using the MTS assay. PrP 106–126, but not
scrambled peptide, altered the metabolic activity of SH-SY5Y (white
bars) and wtPrP (black bers) cells in a dose-dependent manner. No
significant differences were observed in relation with the level of
PrPc expression. Each value represents the mean percentage 6 SD
from triplicate experiments repeated three times (nine observations).
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cell line. In the present work we were mainly interested
on the potential implication of palmitic acid, a represen-
tative cell membrane fatty acid, in this resistance.
To evaluate whether palmitic acid triggered PrP
106–126 cytotoxicity, we determined the synergistic
toxic effect of palmitic acid and prion peptide on the
neuronal (SH-SY5Y) and non neuronal (A74) cell lines.
Cell viability as measured by MTS assay is shown in Fig-
ureF8 8. We compared the viability of the palmitic acid
pre-treated cells after a 24 hr exposure to 200 lM PrP
106–126. As expected, PrP 106–126 led to a 50% sur-
vival for the neuronal cell line (SH-SY5Y) whereas no
toxicity was observed for the rabbit kidney epithelial cell
line (A74). In contrast, SH-SY5Y pre-treated with pal-
mitic acid showed significant susceptibility to the toxic
effect of prion peptide with a cell death increase of 10%,
whereas palmitic acid alone did not affect cell viability.
Surprisingly, the non neuronal A74 cell line pre-treated
with palmitic acid remained resistant to the PrP 106–
126 toxicity.
DISCUSSION
PrP 106–126 peptide is a useful model for the in
vitro study of prion-induced cell suffering. Indeed, this
peptide exhibits some of the pathogenic and physico-
chemical properties of PrPsc. It is able to form protease-
resistant fibrils, induce neuronal toxicity, and has a rela-
tively high b-sheet content (Tagliavini et al., 2001).
However the mechanism by which this peptide induces
alterations in neuronal cells is not well understood. Does
this occur by direct membrane interactions or via mem-
brane receptors?
We have studied the relationship between the
expression of PrPc, the lipidic membrane composition,
and the toxicity induced by the prion peptide 106–126.
It is widely accepted that PrPc is necessary for the
toxicity of PrPsc (Bueler et al., 1993; Brandner et al.,
1996). This dependence on PrPc and toxicity of PrP
106–126 has also been indicated (Brown et al., 1994;
Chabry et al., 2003b; Fioriti et al., 2005d). Nevertheless,
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Fig. 3. Effect of PrP 106–126 on
intracellular ATP levels of cells. SH-
SY5Y (white bars) or wtPrP (black
bars) were treated for 24 hr with differ-
ent concentrations of PrP 106–126 (10–
200 lM). Data are expressed as a per-
centage of control (non-PrP 106–126
treated cells) and represent the mean
percentage 6 SD from triplicate experi-
ments repeated three times (nine obser-
vations).
Fig. 4. Flow cytometry detection of PrPc expression in the absence (A) or in the presence (B) of
SAF 34. SH-SY5Y cells were incubated for 24 hr with the anti-prion antibody SAF 34 and PrPc
was detected with a biotinylated antibody SAF34 (10 lg/ml) for 30 min at 48C (white histogram).
The control cells were not incubated with the antibody biotinylated SAF34 (black histogram).
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Fig. 6. Doxycycline-dependent induction of PrPc expression in A74
cells. Dox was added at different concentrations (0, 10, 25, 50, 100,
500, and 1,000 ng/ml) to medium for 24 hr, and PrPc expression
was determined in A74 cells by Western blot. The equivalent of
20 lg of protein were subjected to SDS-PAGE and PrPc was
detected with antibody P45-66 raised against the N terminus of the
protein. PrPc expression reaches a maximum at 500 ng/ml of dox;
after this concentration we reach a plateau. Molecular mass markers
are indicated on the left in kDa.
Fig. 7. Effect of PrP 106–126 on a rab-
bit kidney epithelial cells (A74) in rela-
tion with the expression level of PrPc.
A74 cells were seeded at 5,000 cells/
well and stimulated with doxycycline
(50 and 500 ng/ml) 24 hr before PrP
106–126 exposure at different concen-
trations: 50 lM (white bars); 100 lM
(black bars). Viability was measured by
MTS assay. Each value represents the
mean percentage 6 SD from triplicate
experiments repeated three times (nine
observations).
Fig. 5. Effect of SAF 34 on the toxicity
induced by PrP106–126 in SH-SY5Y
and wtPrP cells. The viability was mea-
sured in untransfected SH-SY5Y cells
(white bars) or wtPrP-expressing cells
(black bars) both exposed to PrP 106–
126 at 200 lM for 24 hr after a pre-
incubation of 3 hr in the presence or
absence of SAF 34. Each value repre-
sents the mean percentage 6 SD from
triplicate experiments repeated three
times (nine observations).
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the mechanism of toxicity remains unclear and contra-
dictory data about the relation between PrPc expression
and the toxicity induced by PrPsc or PrP 106–126 have
been reported. Several works have shown that the prion
peptide 106–126 is toxic to cultured neurons and that
neurons derived from Prnp/ mice are resistant to this
peptide (Brown et al., 1994; Chabry et al., 2003c). Fior-
iti et al. (2005a) using cerebellar granule neurons derived
from wild-type mice and Tg mice overexpressing mouse
PrP, did not detect any difference in the toxicity of PrP
106–126 on both cell lines. Conversely, they did not
observe any toxicity of the peptide on the knock-out
cell line. These data suggest that the expression of PrPc
is necessary for the toxicity induced by the peptide but
that the level of expression does not modulate this neu-
rotoxicity. The authors propose to explain the toxicity
of PrP 106–126 by the physiologic loss of PrPc. Further-
more, Gu et al. (2001) have shown that in a human
neuronal cell line resistant to the PrP 106–126 toxicity,
the prion peptide binds at the cell surface and that some
of the resistant neuronal cells internalize the peptide that
accumulate in intracellular compartments. They con-
cluded that the resistance to the toxicity induced by PrP
106–126 seemed to be related to an aberrant binding of
the peptide with the membranes. Currently, it is known
that such an aberrant binding with the cellular mem-
brane can be induced by an alteration in the membrane
lipidic composition.
In the present study, we have analyzed the toxicity
of the peptide on a neuroblastoma cell line expressing
different levels of PrPc. Our results show that the toxic-
ity of PrP 106–126 is independent of the expression
level of the cellular prion protein, as shown by Fioriti
and collaborators (Fioriti et al., 2005c). To study the
implication of the endogenous levels of cellular prion
protein in the toxicity induced by the peptide, we have
used an original strategy based on the ability of an anti-
prion antibody (SAF34) to inhibit PrPsc replication and
to decrease the levels of total PrPc and PrPsc in an
infected cell model (Feraudet et al., 2005b). We have
shown by MTS assay that an incubation of SH-SY5Y
with SAF34 did not reduce the toxic effect of the pep-
tide 106–126 indicating that endogenous levels of the
cellular prion protein is not directly implicated in the
toxicity of the peptide. Because we cannot exclude the
possibility that residual PrPc is left in our cells after the
antibody treatment, we propose that a sub-physiological
level or an appropriated lipid composition could be
required for peptide toxicity.
Our finding is consistent with other reports indi-
cating that the toxicity of PrPsc and PrP 106–126 is in-
dependent of the expression of PrPc. Indeed, it has been
shown that PrPsc and PrP 106–126 may cause an upre-
gulation of the MAP kinases signalling pathway inducing
neurotoxicity in Prnp/ cells (Gavin et al., 2005; Mar-
ella et al., 2005). Furthermore, McHattie et al. (1999)
have studied the cellular trafficking of the prion peptide
106–126 and have observed that cultured cells are capa-
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Myristic acid 1,129 923
Nentadecyclic acid 144 674
Nalmitic acid 10,247 5,765
Nalmitoleic acid 1,276 701
Stearic acid 3,596 2,460
T-vaccenic acid 187 68
Oleic acid 8,928 8,814
C-vaccenic acid 3,165 195
Linolenic acid 572 520
Gamma linolenic acid 25 22
Alpha linolenic acid 49 32
Gadoleic acid 209 329
Dihomo-g-linolenic acid 124 177
Arachidonic acid 1,974 1,390
Eicosapentaenoic acid 96 612
Docosapentaenoic acid 999 98
Docosahexaenoic acid 2,420 1,280
Fig. 8. Effect of palmitic acid on the
toxicity induced by PrP 106–126 in
SH-SY5Y and A74 cells. The viability
was measured in SH-SY5Y cells (white
bars) and A74 cells (black bars) both
exposed to PrP 106–126 at 200 lM for
24 hr after a pre-incubation of 16 hr in
the presence or absence of palmitic acid
(25 lM). Each value represents the
mean percentage 6 SD from triplicate
experiments repeated three times (nine
observations).
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ble of sequestering the peptide independent of PrPc
expression.
These results suggest that the toxic mechanism of
this peptide is independent of a direct interaction with
PrPc and indicate that a direct insertion of PrP 106–126
into the cell membrane, particularly in cholesterol-rich
lipid domains, named rafts, could induce disturbances.
We have shown recently that the 106–126 peptide de-
stabilizes lipid vesicles mimicking the composition of
neuronal membranes and that it induces liposome fusion.
This destabilization occurred via a membrane interaction
as was shown by the integrity membrane assay (Dupier-
eux et al., 2005c).
Using a non-neuronal cell line in which the
expression of PrPc could be selectively induced by doxy-
cycline (Vilette et al., 2001a), no toxicity was observed
in the presence and in the absence of PrPc. These data
are in agreement with the results obtained on the neuro-
blastoma cells and suggest that the toxicity induced by
PrP 106–126 could be dependent on the composition of
the cellular membrane as was shown by the fatty acids
analysis. We have observed that the effect of toxicity
induced by the PrP 106–126 prion peptide was more
pronounced in the presence of palmitic acid whereas, no
effect was observed for the non-neuronal cell line A74.
The mechanism as to how palmitic acid could increase
the prion peptide toxicity was not investigated in the
present study and needs to be further explored; these
results must be thoroughly studied by testing different
other lipid factors but at the current state of the work,
we can suggest that the palmitic acid enhances binding
or internalization of the peptide into the lipid mem-
brane. It has been reported that fatty acids with longer
acyl chains (C12–18) cause a reduction in the fluidity
of the cellular membranes affecting cell membrane func-
tion (Johnson et al., 2003) and inducing apoptosis. Our
results seem to indicate that the cellular membrane
fatty acid composition could be an important modulator
factor in the neurodegeneration observed in prion pa-
thology. This is probably by altering the physicochemi-
cal properties of cell membranes favoring the membrane
interaction of pathologic prion protein with the cell
membranesAQ5 .
In conclusion, we reinforce the hypothesis that the
toxicity induced by the prion peptide 106–126 may not
be due only to direct interaction with PrPc and that the
key event in this toxicity could be a direct interaction
with the lipidic components of cell membranes. A desta-
bilization of membrane lipids could interfere with PrPc
function and may facilitate access of the peptide to intra-
cellular targets.
Our current results reinforce previous observations
(Chen et al., 1995; Jeffrey et al., 2004b) proposing that,
during prion diseases, the novo-transconformed PrPsc
could be cleaved in toxic prion protein fragments re-
sponsible of neuronal dysfunction and death. Even more,
these peptides may diffuse and intoxicate adjacent PrP-
negative cells; this hypothesis might explain neuronal
death in transgenic mice knock-out for the Prnp gene
except in astrocytes after PrPsc infection (Jeffrey et al.,
2004a).
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